Cochrane · systematic review · CD003277
Anti‐seizure medications for Lennox‐Gastaut syndrome
Brigo, F, Jones, K, Eltze, C, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
33
current version
GRADE rated
15
No studies
18
Included studies
NR
No studies 18 · 54.5%Ungraded 0 · 0%Very low 3 · 9.1%Low 8 · 24.2%Moderate 0 · 0%High 4 · 12.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs compared to placebo plus ASMs
Population: Lennox‐Gastaut syndrome, any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants free from all seizures Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 75% reduction in all seizures Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 50% reduction in all seizures Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with adverse events leading to study discontinuation Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs | RR 6.62 [1.56, 28.15] | 2 studies · 396 participants | High |
Cinromide plus ASMs compared to placebo plus ASMs
Population: Lennox‐Gastaut syndrome, any age1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants free from all seizures Cinromide plus ASMs vs placebo plus ASMs | no estimate extracted | 1 study · 56 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants with ≥ 75% reduction in mean weekly seizures Cinromide plus ASMs vs placebo plus ASMs | Peto OR 9.35 [0.45, 194.96] | 1 study · 56 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants with ≥ 50% reduction in mean weekly seizures Cinromide plus ASMs vs placebo plus ASMs | RR 1.15 [0.47, 2.86] | 1 study · 56 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants with adverse events leading to study discontinuation Cinromide plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Clobazam (low, medium and high doses) plus ASMs compared to placebo plus ASMs
Population: Lennox‐Gastaut syndrome, any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants free from all seizures Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 75% reduction in all seizures Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 50% reduction in all seizures Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with adverse events leading to study discontinuation Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs | RR 4.12 [1.01, 16.87] | 1 study · 238 participants | High |
Felbamate plus ASMs compared to placebo plus ASMs
Population: Lennox‐Gastaut syndrome, any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants free from all seizures (recorded by closed‐circuit television and electroencephalography) ‐ Felbamate plus ASMs vs placebo plus ASMs | RR 2.92 [0.32, 26.77] | 1 study · 73 participants | Low Downgraded: imprecision |
Number of participants free from all seizures Felbamate plus ASMs vs placebo plus ASMs | no estimate extracted | 1 study · 73 participants | Low Downgraded: imprecision |
Number of participants with ≥ 75% reduction in all seizures Felbamate plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 50% reduction in all seizures Felbamate plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with adverse events leading to study discontinuation Felbamate plus ASMs vs placebo plus ASMs | RR 0.97 [0.06, 14.97] | 1 study · 73 participants | Low Downgraded: imprecision |
Lamotrigine plus ASMs compared to placebo plus ASMs
Population: Lennox‐Gastaut syndrome, any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants free from all seizures Lamotrigine plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 75% reduction in all seizures Lamotrigine plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 50% median reduction in all seizures Lamotrigine plus ASMs vs placebo plus ASMs | RR 2.12 [1.19, 3.76] | 1 study · 167 participants | High |
Number of participants with adverse events leading to study discontinuation Lamotrigine plus ASMs vs placebo plus ASMs | RR 0.49 [0.13, 1.82] | 1 study · 169 participants | Low Downgraded: imprecision |
Rufinamide plus ASMs compared to placebo plus ASMs
Population: Lennox‐Gastaut syndrome, any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants free from all seizures Rufinamide plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 75% reduction in all seizures Rufinamide plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 50% reduction in all seizures Rufinamide plus ASMs vs placebo plus ASMs | RR 2.84 [1.31, 6.18] | 1 study · 138 participants | High |
Number of participants with adverse events leading to study discontinuation Rufinamide plus ASMs vs placebo plus ASMs | RR 4.14 [0.49, 34.86] | 1 study · 59 participants | Low Downgraded: imprecision |
Rufinamide plus ASMs compared to other ASM plus ASMs
Population: Lennox‐Gastaut syndrome, any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants free from all seizures Rufinamide plus ASMs vs other ASM plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 75% reduction in all seizures Rufinamide plus ASMs vs other ASM plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 50% reduction in all seizures Rufinamide plus ASMs vs other ASM plus ASMs | no estimate extracted | NR | No studies |
Number of participants with treatment‐emergent adverse events leading to study discontinuation Rufinamide plus ASMs vs other ASM plus ASMs | RR 0.96 [0.1, 9.57] | 1 study · 37 participants | Low Downgraded: imprecision |
Topiramate plus ASMs compared to placebo plus ASMs
Population: Lennox‐Gastaut syndrome, any age
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants free from all seizures Topiramate plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with ≥ 75% reduction in all seizures Topiramate plus ASMs vs placebo plus ASMs | Peto OR 8.22 [0.6, 112.62] | 1 study · 98 participants | Low Downgraded: imprecision |
Number of participants with ≥ 50% reduction in all seizures Topiramate plus ASMs vs placebo plus ASMs | no estimate extracted | NR | No studies |
Number of participants with adverse events leading to study discontinuation Topiramate plus ASMs vs placebo plus ASMs | no estimate extracted | 1 study · 98 participants | Low Downgraded: imprecision |